Key facts
- This page summarizes Joel S. Marcus's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Mar 2022, 20:49.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.72 to $53.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F2
Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
SEC remarks
Excludes shares previously reported as indirectly held through Alexandria Venture Investments, LLC as it was subsequently determined that the Reporting Person does not have a reportable beneficial ownership interest in the securities held by such entity for purposes of Section 16.